Proactive Investors - Run By Investors For Investors

MaxCyte shows off CARMA platform at industry conference in Washington DC

One of CARMA’s key differentiators is that it can be used to manufacture drug candidates within a single day, providing a “meaningful reduction” in wait times for patients
cancer cell
A phase I study of MaxCyte’s first CARMA drug, MCY-M11, is underway in ovarian cancer patients

MaxCyte Inc (LON:MXCT) has been showing off its CARMA cell therapy platform at an industry conference in Washington DC.

Earlier this week, MaxCyte’s director of technical operations, Robert Keefe, gave a speech at the American Society of Gene and Cell Therapy.

LOOK: Scroll to page 40 to see Keefe’s presentation

He highlighted the potential to manufacture drug candidates on the platform within a day, providing a much-needed faster turnaround of autologous cell therapy to patients.

Keefe also discussed the manufacturing feasibility data for MaxCyte’s first CARMA drug candidate, MCY-M11, which is currently undergoing a phase I study in 15 women with ovarian cancer and peritoneal mesothelioma.

“The advancement of our first CARMA clinical trial, which is consistently showing the feasibility of our rapid manufacturing process, is significant for MaxCyte and the application of our technology,” said chief medical officer Claudio Dansky Ullmann.

“Development of a cell therapy with application in solid tumours is impactful for patients with unmet needs in a variety of cancers and we look forward to further advancing this program.”

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Related Articles

scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use